MA42828A - Plate-forme d'échafaudage à noeud de cystine - Google Patents

Plate-forme d'échafaudage à noeud de cystine

Info

Publication number: MA42828A
Authority: MA; Morocco
Prior art keywords: cystine knot; scaffolding platform; scaffolding; platform; cystine
Prior art date: 2015-09-15

Application number

MA042828A

Other languages

English (en)

Inventor

Xinxin Gao

Rami Hannoush

Harini Kaluarachchi

Aaron NILE

Cameron Noland

Yingnan Zhang

Lijuan Zhou

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-15

Filing date

2016-09-15

Publication date

2018-07-25

2016-09-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2018-07-25 Publication of MA42828A publication Critical patent/MA42828A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Botany (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA042828A 2015-09-15 2016-09-15 Plate-forme d'échafaudage à noeud de cystine MA42828A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562219063P	2015-09-15	2015-09-15

Publications (1)

Publication Number	Publication Date
MA42828A true MA42828A (fr)	2018-07-25

Family

ID=57068206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042828A MA42828A (fr)	2015-09-15	2016-09-15	Plate-forme d'échafaudage à noeud de cystine

Country Status (22)

Country	Link
US (8)	US10428125B2 (fr)
EP (1)	EP3350215B1 (fr)
JP (2)	JP7166916B2 (fr)
KR (1)	KR102846388B1 (fr)
CN (4)	CN114591422B (fr)
AR (1)	AR106032A1 (fr)
AU (2)	AU2016323445B2 (fr)
BR (1)	BR112018002263A2 (fr)
CA (1)	CA2996006A1 (fr)
CL (2)	CL2018000668A1 (fr)
CO (1)	CO2018002510A2 (fr)
CR (1)	CR20180169A (fr)
IL (2)	IL257399B (fr)
MA (1)	MA42828A (fr)
MX (1)	MX2018002922A (fr)
MY (1)	MY190552A (fr)
PE (1)	PE20181293A1 (fr)
PH (1)	PH12018500577A1 (fr)
RU (1)	RU2770384C2 (fr)
TW (1)	TWI799366B (fr)
UA (1)	UA125505C2 (fr)
WO (1)	WO2017049009A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI799366B (zh)	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺
WO2019233605A1 (fr) *	2018-06-08	2019-12-12	BioNTech SE	Compositions et méthodes pour le diagnostic et le traitement du cancer
CA3183808A1 (fr)	2020-06-11	2021-12-16	Genentech, Inc.	Conjugues de nanolipoproteine-polypeptide et compositions, systemes et procedes les utilisant
WO2025193946A2 (fr) *	2024-03-14	2025-09-18	Genentech, Inc.	Peptides se liant à lrrc15 et leurs utilisations

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US918814A (en)	1907-10-30	1909-04-20	Handy Mfg Company	Funnel.
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
ATE158615T1 (de)	1990-03-20	1997-10-15	Univ Columbia	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (fr)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
US5961955A (en) *	1997-06-03	1999-10-05	Coulter Pharmaceutical, Inc.	Radioprotectant for peptides labeled with radioisotope
CZ20003099A3 (cs)	1998-02-25	2002-04-17	Lexigen Pharmaceuticals Corporation	Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
JP2003528632A (ja)	2000-03-31	2003-09-30	インスティティ・パスツール	血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
AU2001265198A1 (en)	2000-06-01	2001-12-11	Amgen Inc.	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
DE60239868D1 (de)	2001-06-12	2011-06-09	Univ Johns Hopkins Med	Reservoirvorrichtung für die intraokulare arzneimittelabgabe
WO2003029275A2 (fr)	2001-10-03	2003-04-10	Regeneron Pharmaceuticals, Inc.	Peptides anti-angiogeniques
GB0130738D0 (en)	2001-12-21	2002-02-06	Serono Internat S A	Protein
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2005110374A1 (fr)	2004-04-30	2005-11-24	Allergan, Inc.	Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere
US20060182783A1 (en)	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
DE102005002978B4 (de)	2005-01-21	2013-04-25	Merz Pharma Gmbh & Co. Kgaa	Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP1844337B1 (fr)	2005-01-24	2013-07-03	Pepscan Systems B.V.	Composes liants, composes immunogenes et composes peptidomimetiques
US20060204548A1 (en)	2005-03-01	2006-09-14	Allergan, Inc.	Microimplants for ocular administration
JP2008546821A (ja)	2005-06-29	2008-12-25	ロゼリ、パトリツィア	Ｖｅｇｆ受容体を制御する化合物、およびその使用
CN101583370A (zh) *	2005-09-27	2009-11-18	阿穆尼克斯公司	蛋白质药物及其用途
WO2007038619A2 (fr) *	2005-09-27	2007-04-05	Amunix, Inc.	Produits pharmaceutiques proteiques et utilisations de ceux-ci
TW200732347A (en) *	2005-10-06	2007-09-01	Trophogen Inc	VEGF analogs and methods of use
US7918814B2 (en)	2006-05-02	2011-04-05	Georgia Tech Research Corporation	Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (fr) *	2006-10-04	2008-04-17	The Board Of Trustees Of The Leland Stanford Junior University	Peptides modifies de liaison aux integrines
US8039010B2 (en)	2006-11-03	2011-10-18	Allergan, Inc.	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2670990A1 (fr)	2006-12-01	2008-06-12	Allergan, Inc.	Procede pour determiner des emplacements oculaires optimaux pour des systemes d'administration de medicament
EP2187968A4 (fr)	2007-08-21	2013-02-20	Univ Texas	Mélange thermocinétique pour des applications pharmaceutiques
WO2009120922A2 (fr) *	2008-03-27	2009-10-01	Zymogenetics, Inc.	Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
US8557273B2 (en)	2008-04-18	2013-10-15	Medtronic, Inc.	Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en)	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
EP2349327A4 (fr) *	2008-10-23	2012-11-28	Massachusetts Inst Technology	Engagement dirigé de récepteurs fc activateurs
WO2010060748A1 (fr) *	2008-11-03	2010-06-03	Molecular Partners Ag	Protéines de liaison inhibant l’interaction du récepteur vegf-a
AU2010208046B2 (en)	2009-01-29	2014-10-02	Forsight Vision4, Inc.	Posterior segment drug delivery
US8778888B2 (en) *	2009-11-06	2014-07-15	The Board Of Trustees Of The Leland Stanford Junior University	Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en)	2009-12-21	2011-08-25	Adrian Raiche	Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
EP2515864A4 (fr)	2009-12-23	2013-09-11	Psivida Inc	Dispositifs d'administration à libération prolongée
US8339139B2 (en) *	2010-01-29	2012-12-25	Infineon Technologies Ag	System and method for testing a circuit
AU2011326164B2 (en)	2010-11-08	2016-05-05	The Board Of Trustees Of The Leland Stanford Junior University	Fusion proteins comprising an engineered knottin peptide and uses thereof
KR102014203B1 (ko) *	2011-02-18	2019-08-26	아사나 바이오사이언시스 엘엘씨	아미노인단 화합물 및 통증 치료에서 그것의 용도
US9187553B2 (en) *	2012-01-25	2015-11-17	Swey-Shen Chen	Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP2015528454A (ja) *	2012-08-28	2015-09-28	ノバルティスアーゲー	眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
GB201218278D0 (en) *	2012-10-11	2012-11-28	Cyclogenix Ltd	Translocating peptide
WO2014063012A1 (fr) *	2012-10-19	2014-04-24	The Board Of Trustees Of The Leland Stanford Junior University	Miniprotéines knottines conjuguées contenant des acides aminés non naturels
TWI799366B (zh)	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺

2016
- 2016-09-14 TW TW105130077A patent/TWI799366B/zh active
- 2016-09-15 IL IL257399A patent/IL257399B/en unknown
- 2016-09-15 US US15/267,087 patent/US10428125B2/en active Active
- 2016-09-15 MX MX2018002922A patent/MX2018002922A/es unknown
- 2016-09-15 MA MA042828A patent/MA42828A/fr unknown
- 2016-09-15 AU AU2016323445A patent/AU2016323445B2/en active Active
- 2016-09-15 CR CR20180169A patent/CR20180169A/es unknown
- 2016-09-15 AR ARP160102810A patent/AR106032A1/es unknown
- 2016-09-15 CN CN202210278625.9A patent/CN114591422B/zh active Active
- 2016-09-15 MY MYPI2018000374A patent/MY190552A/en unknown
- 2016-09-15 KR KR1020187010195A patent/KR102846388B1/ko active Active
- 2016-09-15 IL IL294568A patent/IL294568A/en unknown
- 2016-09-15 CN CN202210278014.4A patent/CN114805528A/zh active Pending
- 2016-09-15 RU RU2018113442A patent/RU2770384C2/ru active
- 2016-09-15 PE PE2018000390A patent/PE20181293A1/es unknown
- 2016-09-15 EP EP16775922.4A patent/EP3350215B1/fr active Active
- 2016-09-15 UA UAA201804058A patent/UA125505C2/uk unknown
- 2016-09-15 CN CN202510314078.9A patent/CN120248097A/zh active Pending
- 2016-09-15 JP JP2018513360A patent/JP7166916B2/ja active Active
- 2016-09-15 CN CN201680052527.6A patent/CN108026162B/zh active Active
- 2016-09-15 CA CA2996006A patent/CA2996006A1/fr active Pending
- 2016-09-15 BR BR112018002263-2A patent/BR112018002263A2/en active Search and Examination
- 2016-09-15 WO PCT/US2016/052012 patent/WO2017049009A1/fr not_active Ceased
2018
- 2018-03-07 CO CONC2018/0002510A patent/CO2018002510A2/es unknown
- 2018-03-13 CL CL2018000668A patent/CL2018000668A1/es unknown
- 2018-03-15 PH PH12018500577A patent/PH12018500577A1/en unknown
- 2018-04-03 US US15/944,700 patent/US10696721B2/en active Active
2019
- 2019-08-19 US US16/544,394 patent/US11407794B2/en active Active
- 2019-09-18 US US16/574,910 patent/US11078243B2/en active Active
- 2019-09-18 US US16/574,917 patent/US11155586B2/en active Active
2020
- 2020-06-29 US US16/915,387 patent/US20200325187A1/en not_active Abandoned
- 2020-07-02 CL CL2020001781A patent/CL2020001781A1/es unknown
2021
- 2021-06-28 AU AU2021204400A patent/AU2021204400B2/en active Active
2022
- 2022-06-15 JP JP2022096301A patent/JP7602514B2/ja active Active
- 2022-06-17 US US17/843,595 patent/US20230174596A1/en not_active Abandoned
2023
- 2023-10-30 US US18/497,741 patent/US20240247034A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US11407794B2 (en)	2022-08-09
CN114805528A (zh)	2022-07-29
MY190552A (en)	2022-04-27
AR106032A1 (es)	2017-12-06
US20170129927A1 (en)	2017-05-11
US11155586B2 (en)	2021-10-26
CN120248097A (zh)	2025-07-04
CN108026162B (zh)	2022-04-05
US10696721B2 (en)	2020-06-30
CN114591422A (zh)	2022-06-07
US10428125B2 (en)	2019-10-01
JP2022130481A (ja)	2022-09-06
KR102846388B1 (ko)	2025-08-18
AU2021204400B2 (en)	2023-02-02
EP3350215A1 (fr)	2018-07-25
PH12018500577A1 (en)	2018-10-15
US20200325187A1 (en)	2020-10-15
CR20180169A (es)	2018-04-24
EP3350215B1 (fr)	2025-12-03
US11078243B2 (en)	2021-08-03
US20180291069A1 (en)	2018-10-11
CL2020001781A1 (es)	2020-10-23
CO2018002510A2 (es)	2018-05-31
PE20181293A1 (es)	2018-08-07
RU2018113442A (ru)	2019-10-16
US20230174596A1 (en)	2023-06-08
AU2016323445B2 (en)	2021-04-01
US20200140498A1 (en)	2020-05-07
CN114591422B (zh)	2025-04-04
MX2018002922A (es)	2018-06-07
BR112018002263A2 (en)	2018-09-18
NZ740218A (en)	2025-05-02
TW201717993A (zh)	2017-06-01
JP7166916B2 (ja)	2022-11-08
WO2017049009A1 (fr)	2017-03-23
AU2016323445A1 (en)	2018-03-01
IL257399B (en)	2022-08-01
RU2018113442A3 (fr)	2020-02-17
AU2021204400A1 (en)	2021-07-22
JP7602514B2 (ja)	2024-12-18
CN108026162A (zh)	2018-05-11
US20200231636A1 (en)	2020-07-23
JP2018533912A (ja)	2018-11-22
IL257399A (en)	2018-04-30
UA125505C2 (uk)	2022-04-13
US20200115424A1 (en)	2020-04-16
KR20180052718A (ko)	2018-05-18
TWI799366B (zh)	2023-04-21
RU2770384C2 (ru)	2022-04-15
IL294568A (en)	2022-09-01
HK1253318A1 (zh)	2019-06-14
US20240247034A1 (en)	2024-07-25
WO2017049009A8 (fr)	2018-02-22
CL2018000668A1 (es)	2018-07-20
CA2996006A1 (fr)	2017-03-23

Publication	Publication Date	Title
EP3430731A4 (fr)	2019-10-09	Architecture d'iugw
EP3488670A4 (fr)	2020-03-18	Technologies d'architecture de bâti
PL3649151T3 (pl)	2024-11-04	Białka rusztowania
EP3302575A4 (fr)	2019-01-16	Vecteurs d'édition de génome
EP3387025A4 (fr)	2019-10-09	Compositions d'émulsion inverse
MA42036A (fr)	2018-03-14	Analogues nucléosidiques 5'-substitués
EP3322981A4 (fr)	2019-03-20	Plate-forme de dosage biologique à base de microgouttelettes
EP3379317A4 (fr)	2019-03-20	Lentille d'imagerie
EP3378606A4 (fr)	2020-01-22	Combinaison d'assistance
MA42771A (fr)	2018-07-18	Chaussure perméable à l'air
MA48596A (fr)	2021-03-31	Caractéristique d'inertie
EP3522872A4 (fr)	2020-05-20	Formulations d'amlodipine
EP3302061A4 (fr)	2019-02-27	Compositions d'urée à libération prolongée
EP3354420A4 (fr)	2019-06-12	Dispositif d'actionnement à biellette de type combiné
EP3338446A4 (fr)	2019-12-04	Projections d'image
EP3431808A4 (fr)	2019-04-03	Butée d'arrêt
EP3463259A4 (fr)	2019-12-18	Compositions d'écran solaire
MA42828A (fr)	2018-07-25	Plate-forme d'échafaudage à noeud de cystine
EP3429581A4 (fr)	2019-11-06	Formulations d'énalapril
EP3718414A4 (fr)	2021-08-11	Composition d'émulsion
EP3416672A4 (fr)	2019-09-18	Formulations d'oritavancine
EP3682742C0 (fr)	2023-10-11	Caramel à l'allulose
EP3387469A4 (fr)	2019-08-21	Détermination d'électrofaciès
EP3294278A4 (fr)	2019-01-16	Compositions dissuasives d'abus à base de psychostimulant
EP4190990C0 (fr)	2024-08-21	Échafaudage